Publications by authors named "Donald Small"

Claim this Profile
S
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with mutations to FLT3 inhibitors.
Aditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, Yuchen Liu, Donald Small

bioRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells.
Moran Wang, Ruiqi Zhu, Donald Small, Lan Lin, Li Li

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia.
Tessa S Seale, Li Li, J Kyle Bruner, Melody Chou, Bao Nguyen, Donald Small

Mol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.
Ruiqi Zhu, Courtney M Shirley, S Haihua Chu, Li Li, Bao H Nguyen, Donald Small

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.
Toshihiro Matsukawa, Mianmian Yin, Nupur Nigam, Vijay Negi, Li Li, Donald Small

Leukemia· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.
David J Young, Bao Nguyen, Li Li, Tomoyasu Higashimoto, Mark J Levis, Donald Small

Blood Cancer Discov· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Patrick A Brown, John A Kairalla, Joanne M Hilden, ZoAnn E Dreyer, Andrew J Carroll, Donald Small

Leukemia· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Patrick A Brown, John A Kairalla, Joanne M Hilden, ZoAnn E Dreyer, Andrew J Carroll, Donald Small

Leukemia· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.
David J Young, Bao Nguyen, Ruiqi Zhu, Jaesung Seo, Li Li, Donald Small

Blood Adv· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Ruiqi Zhu, Li Li, Bao Nguyen, Jaesung Seo, Min Wu, Donald Small

Signal Transduct Target Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor.
Pedram Argani, Lei Zhang, Yun-Shao Sung, Marissa J White, Karin Miller, Donald Small

Genes Chromosomes Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Min Wu, Li Li, Max Hamaker, Donald Small, Amy S Duffield

Haematologica· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual binding motifs underpin the hierarchical association of perilipins1-3 with lipid droplets.
Dalila Ajjaji, Kalthoum Ben M'barek, Michael L Mimmack, Cheryl England, Haya Herscovitz, Donald M Small

Mol Biol Cell· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knock-in of the R394W mutation causes MDS and cooperates with to drive aggressive myeloid neoplasms in mice.
Colleen E Annesley, Cara Rabik, Amy S Duffield, Rachel E Rau, Daniel Magoon, Donald Small

Oncotarget· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.
Kozo Nagai, Lihong Hou, Li Li, Bao Nguyen, Tessa Seale, Donald Small

Oncotarget· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
J Kyle Bruner, Hayley S Ma, Li Li, Alice Can Ran Qin, Michelle A Rudek, Donald Small

Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOCK2: A novel FLT3/ITD leukemia drug target.
Min Wu, Donald Small, Amy S Duffield

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.
Nathan L Meyers, Mikael Larsson, Evelina Vorrsjö, Gunilla Olivecrona, Donald M Small

J Lipid Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Bao Nguyen, Allen B Williams, David J Young, Hayley Ma, Li Li, Donald Small

Oncotarget· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Lauren Y Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C Smith, Jayant Ranganathan Raman, Donald Small

Blood· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential role for all- retinoic acid in nonpromyelocytic acute myeloid leukemia.
Hayley S Ma, Tara M Robinson, Donald Small

Int J Hematol Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
Jennifer L Poitras, Diane Heiser, Li Li, Bao Nguyen, Kozo Nagai, Donald Small

Oncotarget· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
Hayley S Ma, Sarah M Greenblatt, Courtney M Shirley, Amy S Duffield, J Kyle Bruner, Donald Small

Blood· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II.
Nathan L Meyers, Mikael Larsson, Gunilla Olivecrona, Donald M Small

J Biol Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Yiting Lim, Lukasz Gondek, Li Li, Qiuju Wang, Hayley Ma, Donald Small

Sci Transl Med· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis